

Diakron Pharmaceuticals
Balance Sheets as of 31st Mar'2022

Presented in U.S.Dollars
Unaudited - Prepared by Management

	Mar 31
	<u>2022</u>
Assets	
Current Assets	
Cash and Equivalents	\$ 64
Total Current Assets	\$ 64
Deposits	\$ 3,164
License Agreement, Net of Amortization	
Service Agreement from Owner	\$ -
Patents, Net of Amortization	\$ -
Total Assets	\$ 3,228
Liabilities and Stockholders' Equity	
Current Liabilities	
Accounts Payable	\$ 34,95,584
Accrued Interest	\$ -
License Agreement Payable	\$ -
Share application funds pending issuance authorization	\$ 3,09,760
Loans from Co- Founders	\$ -
Loans from Officers / Directors	\$ -
Loans - Other	\$ 25,000
Total Current Liabilities	\$ 38,30,344
Total Liabilities	\$ 38,30,344
Stockholders' Equity	
Common Stock, no par value 10,000,000 shares authorized, 2,596,152 issued and outstanding at June 30, 2012	
Preferred Stock, no par value 2,906,873 shares issued and outstanding at September 30, 2008 including shares issued for \$1,000,000 of future research and development from Orchid Chemicals and Pharmaceuticals 3,816,018 shares issued and outstanding after \$760,000 Orchid Chemicals and Pharmaceuticals investment through July 28, 2010. 7,140,378 shares issued and outstanding as of July 17, 2013.	
Additional Paid-in Capital	\$ 71,17,030
Services Agreement from Owner	\$ -
Accumulated Deficit	\$ -1,09,44,146
Total Stockholders' Equity	\$ -38,27,116
Total Liabilities and Stockholders' Equity	\$ 3,228

Diakron Pharmaceuticals
Statements of Operations
For the Period Apr'2021 to Mar'2022

Presented in U.S.Dollars
Unaudited - Prepared by Management

Apr'2021-Mar'2022

Expenses:

Research & Development - Patents & Licenses	\$	-
License Impairment		
Accounting, Taxes, Legal Fees & Travel	\$	-
Consulting	\$	-
Office Expense	\$	-
Stock Option Compensation Expense		
Clinical Expenses	\$	-
Services from Owner Agreement - Amortized		
Other Expense / Interest Expense	\$	-
Total Expenses	\$	-
Other Income - Debt Settlement Income		
Net (Loss)	\$	-